Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

- VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma remains on track ...

Related Keywords

Spain ,Rockville ,California ,United States ,Madrid ,San Diego ,American ,Stevena Shallcross ,Chris Calabrese ,Institut Catala ,Ricard Mesia ,Md Institut Catal ,Theriva Biologics ,European Society For Medical Oncology ,Society For Immunotherapy Of Cancer ,Company Annual Report On Form ,Lifesci Advisors ,Net Loss Attributable To Theriva Biologics Inc ,Oncologia Catalan Institute Of Oncology ,University Of Pennsylvania ,Pancreatic Ductal Adenocarcinoma ,European Society ,Medical Oncology ,Chief Executive Officer ,Albumin Shield ,Program Highlights ,Anticipated Milestones ,Institut Catal ,Catalan Institute ,Quarter Ended September ,Theriva Biologic ,Private Securities Litigation Reform Act ,Annual Report ,Sci Advisors ,Temporary Equity ,Operating Costs ,Loss Attributable ,Loss Per Share ,